RxDoctor Payments Data

Jennifer Sizemore, PA

Physician Assistant · London, KYNPI 1083706774

Payments from drug & device makers

$4,281in general payments, 2019–2025

Across 260 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$973
  • Novartis$901
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$647
  • Merck$406
  • Abbott$221
  • Sanofi-aventis U.S. LLC$214
  • plus $917 from 18 others

What the payments were for

  • Food & beverage$4,20398%
  • Education$782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,281 in reported general payments places this provider in the 90th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$36,910
Medicare patients
350
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban635$517,041
EntrestoSacubitril/Valsartan89$87,917
MultaqDronedarone Hcl70$86,320
XareltoRivaroxaban64$61,594
FarxigaDapagliflozin Propanediol39$32,352
JardianceEmpagliflozin31$25,309
Ranolazine ErRanolazine179$21,090
Repatha SureclickEvolocumab18$10,683
SotalolSotalol Hcl351$5,377
Isosorbide Mononitrate ErIsosorbide Mononitrate452$2,388
Amiodarone Hcl212$2,297
Metoprolol Succinate312$1,989
Midodrine Hcl47$1,724
Digoxin92$1,290
Metoprolol Tartrate426$1,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$973$517,041635 claims
NovartisEntresto$901$87,91789 claims
Sanofi-aventis U.S. LLCMultaq$214$86,32070 claims
Johnson & JohnsonXarelto$12$61,59464 claims
AstraZenecaFarxiga$38$32,35239 claims
Boehringer IngelheimJardiance$24$25,30931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in London

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →